Q4 2022 Cantargia AB Earnings Call Transcript
¶ -
Thank you so much. It's a pleasure to be here and present the full-year report for Cantargia. And it's an extra pleasure to do it on the back of a very important press release this morning on new data in triple-negative breast cancer.
So let's go into the story. So besides myself, as you said, it will be Bengt Jöndell, CFO, who will do a presentation. And it's been a good period. And it's been a very good year for Cantargia, even though it's been a very, let's say, dramatic and difficult year for the world.
And during the period and after the period, we have significantly, let's say, focused our clinical activities by stopping three clinical trials, to let them readout during this year and focus on what we believe is three very different but very promising opportunities, with our lead program, nadunolimab. And we will go through that in detail later on.
And as I said, one of these opportunities, which are the TRIFOUR trial in triple-negative breast cancer, the first dose escalation part was completed. And we were very happy
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
